NIH’s Robert Gallo
Formal investigation "is warranted" of Gallo's National Cancer Institute Laboratory, National Institutes of Health Acting Director William Raub announced Oct. 5. The investigation will focus on several aspects of published reports from Gallo's lab, particularly the article by Mika Popovic, et al., published in the May 1984 issue of Science, that first described HIV. The investigation will also conduct tests to determine the origins of the HTLV-IIIB virus that Gallo and his colleagues used to develop the blood test for HIV. Raub noted that the initial inquiry into Gallo's research by NIH's Office of Scientific Integrity "has resolved certain of the publicized allegations and issues or shown them to be without substance. In particular, the inquiry team has concluded that Dr. Gallo had a substantial number of HIV detections and isolations from several different sources at the critical time that HTLV-IIIB (the principal virus isolated by the Gallo laboratory) and LAV (the virus isolated by the Pasteur Institute) were being grown in Gallo's laboratory".
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.